BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed Price. Currency in USD
52.77
+0.08 (+0.15%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close52.69
Open52.81
Bid0.00 x 1000
Ask0.00 x 4000
Day's Range52.54 - 53.00
52 Week Range49.96 - 70.05
Volume3,735,456
Avg. Volume8,494,774
Market Cap86.28B
Beta1.04
PE Ratio (TTM)86.51
EPS (TTM)0.61
Earnings DateJul 25, 2018 - Jul 30, 2018
Forward Dividend & Yield1.60 (3.07%)
Ex-Dividend Date2018-04-05
1y Target Est58.30
Trade prices are not sourced from all markets
  • Label Expansion May Boost Opdivo’s Revenues in 2018
    Market Realist2 days ago

    Label Expansion May Boost Opdivo’s Revenues in 2018

    Bristol-Myers Squibbs (BMY) is anticipating key data readouts from multiple phase 3 trials evaluating Opdivo in indications such as gastric cancer, head and neck cancer, small cell lung cancer, and hepatocellular carcinoma, by the end of 2019. On April 18, Bristol-Myers Squibb announced that the FDA had granted priority review for a supplemental biologics application (or sBLA) seeking approval for Opdivo in the third-line small cell lung cancer (or SCLC) indication. The Prescription Drug User Fee Act (or PDUFA) date for this application has been set for August 16.

  • Opdivo May Witness Decline in This Target Patient Population
    Market Realist2 days ago

    Opdivo May Witness Decline in This Target Patient Population

    At end of Q1 2018, Bristol-Myers Squibb’s (BMY) Opdivo earned 40% of its revenues in the US market from the lung cancer indication, while the remaining US market revenues were attributable to demand for the drug in other tumor types. By the end of Q1 2018, the drug had managed to maintain its market share in the second-line lung cancer segment in the US.

  • Lenvima’s Approval in Japan Is Expected to Drive Merck’s Growth
    Market Realist2 days ago

    Lenvima’s Approval in Japan Is Expected to Drive Merck’s Growth

    In March, Merck & Company (MRK) and Eisai announced that Lenvima had received approval in Japan for the treatment of individuals with unresectable hepatocellular carcinoma (or HCC). Globally, Lenvima’s approval for the treatment of HCC in Japan became its first approval worldwide for the treatment of unresectable HCC.

  • Opdivo Continues to Be Key Growth Driver for Bristol-Myers Squibb
    Market Realist2 days ago

    Opdivo Continues to Be Key Growth Driver for Bristol-Myers Squibb

    In the first quarter, Bristol-Myers Squibb’s (BMY) Opdivo witnessed sales close to $1.5 billion, driven by a robust rise in demand across the approved indications of lung cancer, renal cell carcinoma (or RCC), head and neck cancer, and melanoma. Further, the company is also witnessing robust uptake of Opdivo as adjuvant therapy for melanoma patients. To know more about Opdivo as an adjuvant melanoma therapy, please read Opdivo Could Be Key Revenue Driver for Bristol-Myers Squibb in 2018.

  • This Collaboration Is Expected to Boost Merck’s Long-Term Growth
    Market Realist2 days ago

    This Collaboration Is Expected to Boost Merck’s Long-Term Growth

    Merck & Company (MRK) has entered into a global strategic oncology collaboration with Eisai for the worldwide codevelopment and co-commercialization of Eisai’s Lenvima. Merck and Eisai will jointly develop and commercialize Lenvima as a monotherapy and in combination with Keytruda.

  • Business Wire4 days ago

    Bristol-Myers Squibb to Hold Investor Event to Discuss ASCO Highlights

    Bristol-Myers Squibb Company (BMY) will hold an investor event on Monday, June 4, 2018 at 8:30 p.m. EDT (7:30 p.m. CDT) to discuss data presented at the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of data presented from the company’s oncology portfolio, and address questions from investors and analysts. Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

  • Why Big Pharma is finally discovering the Bay Area
    American City Business Journals4 days ago

    Why Big Pharma is finally discovering the Bay Area

    AstraZeneca formally opened its 163,000-square-foot lab and office complex Tuesday in HCP Inc.'s Britannia Cove in South San Francisco. It joins Merck and Bristol-Myers Squibb as traditional drug maker to expand operations in the Bay Area.

  • Warren Buffett Loves TEVA Stock and You Should Too
    InvestorPlace5 days ago

    Warren Buffett Loves TEVA Stock and You Should Too

    While Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE:TEVA) faded from last Wednesday highs, shares ultimately climbed about 3% that day. No, it wasn’t earnings or a new drug that gave TEVA stock a bump. Instead, it was Warren Buffett.

  • ACCESSWIRE7 days ago

    Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space

    Major equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Co. (NYSE: BMY), Eli Lilly and Co. (NYSE: LLY), and GW Pharmaceuticals PLC (NASDAQ: GWPH). All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Exelixis Is Focused on Management of the Cabozantinib Franchise
    Market Realist9 days ago

    Exelixis Is Focused on Management of the Cabozantinib Franchise

    Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.

  • Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018
    Market Realist9 days ago

    Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018

    In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume driven by both new patient starts and a robust rise in the total number of patients on the therapy. According to a report, ~295,000 people across the world are diagnosed with kidney cancer every year, while 134,000 kidney cancer patients die every year. According to the American Cancer Society’s Cancer Facts & Figures 2018, the annual incidence of kidney cancer in the United States is ~65,000, while the annual death toll of the disease is 15,000. Another report estimates that almost 70%–75% of renal cell cancer (or RCC) patients suffer from clear cell RCC.

  • Immunomedics Announces Positive Phase 2 Results
    Market Realist10 days ago

    Immunomedics Announces Positive Phase 2 Results

    Today, Immunomedics (IMMU) announced positive results from a Phase 2 trial evaluating its investigational antibody drug conjugate (or ADC) sacituzumab govitecan in patients suffering from estrogen receptor-positive (or ER+)/human epidermal growth factor receptor 2-negative (or HER2-) metastatic breast cancer who have previously received at least two therapies. The investigational ADC therapy demonstrated an overall response rate of 31% in these heavily pretreated patients. Immunomedics plans to file its first biologics license application with the FDA later this month for the approval of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer (mTNBC).

  • Exelixis Is Expected to Report a Robust Revenue Rise in 2018
    Market Realist10 days ago

    Exelixis Is Expected to Report a Robust Revenue Rise in 2018

    The company reported net income of close to $115.9 million in the quarter, a YoY rise of ~594% and a sequential rise of 201%. Exelixis reported diluted GAAP (generally accepted accounting principles) EPS (earnings per share) of close to $0.37, a YoY rise of ~585% and a sequential rise of 201%. Analysts expect Exelixis to report revenue of close to $723 million in 2018, a YoY rise of ~59.8%.

  • Why Exelixis Stock Fell Last Week
    Market Realist10 days ago

    Why Exelixis Stock Fell Last Week

    On May 11, Exelixis’s (EXEL) closing price was $19.55, almost 12.9% lower than its closing price on May 4. This fall was mainly attributable to unfavorable results released from its Phase 3 IMblaze370 study comparing a combination regimen of Cotellic (cobimetinib) with Roche Holdings’ (RHHBY) Tecentriq (atezolizumab) compared to Bayer’s Stivarga in locally advanced or metastatic colorectal cancer indications. Exelixis and Roche Holdings’ investigational combination regimen failed to demonstrate a statistically significant improvement in the primary end point of overall survival compared to Stivarga in difficult-to-treat patients who had witnessed disease progression or had been unable to tolerate at least two chemotherapy treatments.

  • Business Wire11 days ago

    Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018

    Bristol-Myers Squibb Company today announced that data from over 70 Company-sponsored studies and collaborations evaluating its oncology compounds across more than 20 types of cancer will be featured at the American Society of Clinical Oncology Annual Meeting 2018 in Chicago from June 1-5.

  • A Look at Gilead Sciences’ Competitive Scenario
    Market Realist11 days ago

    A Look at Gilead Sciences’ Competitive Scenario

    Gilead Sciences’ (GILD) Viread sales decreased 63% from $260 million in Q1 2017 to $97 million in Q1 2018. Epclusa sales, which accounted for 12% of Gilead’s total antiviral product sales in the first quarter, decreased from $892 million in Q1 2017 to $536 million in Q1 2018.

  • Benzinga12 days ago

    Jim Cramer Advises His Viewers On Consolidated Edison, L Brands And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said he would not buy Chesapeake Energy Corporation (NYSE: CHK ) because there's too much natural gas. Cramer would take profits in Adaptimmune ...

  • CNBC12 days ago

    Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares for now

    It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Clorox : "Clorox is caught up in this whole vortex of the 10-year Treasury going above 3 percent yield.

  • InvestorPlace12 days ago

    Nektar Therapeutics Stock Is Risky But Offers Big Reward

    After topping the $110 level in March 2018, shares of Nektar Therapeutics (NASDAQ:NKTR) are in a downtrend. It is worth noting that even though Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Endo International PLC (NASDAQ:ENDP) are starting to attract investors, NKTR stock is more attractive because of the drug’s inherent properties. Nektar collaborated with Bristol-Myers Squibb Company (NYSE:BMY) to develop NKTR-214 in clinical trials.

  • Bristol-Myers Squibb’s Cash Flows and Valuation Metrics
    Market Realist12 days ago

    Bristol-Myers Squibb’s Cash Flows and Valuation Metrics

    Bristol-Myers Squibb (BMY) generated $1.1 billion from operating activities in 1Q18, which compares to $861 million in 1Q17. The increase was primarily attributable to the timing of cash collections and payments in business operations of ~$800 million, partially offset by lower litigation settlement proceeds of ~$500 million related to Merck’s Keytruda in 2017.

  • Exploring Bristol-Myers Squibb’s Financial Performance
    Market Realist12 days ago

    Exploring Bristol-Myers Squibb’s Financial Performance

    Bristol-Myers Squibb’s (BMY) total revenues have increased 5%, from $4.9 billion in 1Q17 to $5.2 billion in 1Q18. For fiscal 2018 and 2019, the company is expected to generate total revenues of $21.7 billion and $22.9 billion, respectively.

  • Business Wire13 days ago

    Bristol-Myers Squibb to Take Part in UBS 2018 Global Healthcare Conference

    Bristol-Myers Squibb Company will take part in the UBS 2018 Global Healthcare Conference on Tuesday, May 22, 2018, in New York. Charles Bancroft, executive vice president, Chief Financial Officer and Head of Global Business Operations, will answer questions about the company at 11:30 a.m.

  • How Bristol-Myers Squibb’s Key Products Performed in 1Q18
    Market Realist13 days ago

    How Bristol-Myers Squibb’s Key Products Performed in 1Q18

    Bristol-Myers Squibb’s (BMY) prioritized brands include Opdivo, Eliquis, Orencia, Sprycel, Yervoy, and Empliciti. Total Opdivo sales increased 34%, from $1.1 billion in 1Q17 to $1.5 billion in 1Q18. The drug registered strong growth in the US market as well as non-US markets. Its US sales increased 23%, from $761 million in 1Q17 to $938 million in 1Q18. Opdivo’s non-US sales increased 57%, from $366 million in 1Q17 to $573 million in 1Q18.

  • What’s Bristol-Myers Squibb’s Business Strategy?
    Market Realist13 days ago

    What’s Bristol-Myers Squibb’s Business Strategy?

    Bristol-Myers Squibb’s (BMY) business strategy is to combine the scale and capabilities of a pharmaceutical company with the speed and agility of an innovation-driven biotechnology industry. The company’s strategic priorities include the following: driving business performance continuing to build a strong IO (immuno-oncology) franchise maintaining a diversified product portfolio maintaining a disciplined approach to capital allocation   Key developments in 2018

  • Cramer's lightning round: Take a pass on Bristol-Myers Sq...
    CNBC Videos12 days ago

    Cramer's lightning round: Take a pass on Bristol-Myers Sq...

    Jim Cramer fires off his take on callers' favorite stocks, including a biopharmaceutical play facing a rival.